News Center

Seplat Energy’s long-term rating upgraded to B2 by Moody’s

Seplat Energy’s long-term rating upgraded to B2 by Moody’s

Investing.com -- Moody’s Ratings has upgraded the long-term corporate family rating (CFR) of Seplat Energy Plc (Seplat) to B2 from Caa1 today. The probability of default rating (PDR) has also been raised to B2-PD from Caa1-PD. The outlook has been changed to stable from positive.The upgrade follows Moody’s decision on May 30, 2025, to upgrade Nigeria’s government bond rating to B3 from Caa1. ...

2025-06-04 01:39:19
Chip stocks lift Wall Street as investors await trade negotiations

Chip stocks lift Wall Street as investors await trade negotiations

By Kanchana Chakravarty and Sukriti Gupta (Reuters) -U.S. stock indexes rose on Tuesday, helped by gains in Nvidia (NASDAQ:NVDA) and other chipmakers, as investors awaited possible negotiations between the United States and its trading partners for more clarity on Washington’s tariff plans. President Donald Trump and Chinese leader Xi Jinping are set to speak this week, the White House said on M ...

2025-06-04 01:34:37
VW’s Wolfsburg plant may move to four-day week from 2027, works council says

VW’s Wolfsburg plant may move to four-day week from 2027, works council says

(Corrects paragraph 6 to show that statistics refer to Golf production globally, not only in Wolfsburg) BERLIN (Reuters) - Volkswagen (ETR:VOWG_p)’s restructuring of its Wolfsburg plant from 2027 to make way for EV-only production could result in a temporary four-day working week at the plant, works council chief Daniela Cavallo told workers on Tuesday. Cavallo, a central figure in negotiations ...

2025-06-04 01:33:12
Exclusive-Wegovy use up 50% among US teens

Exclusive-Wegovy use up 50% among US teens

By Chad Terhune and Robin Respaut LOS ANGELES (Reuters) -American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows. The average rate of teens beginning treatment with the highly effective Novo Nordisk (NYSE:NVO) drug grew 50% last year to 14.8 prescriptions p ...

2025-06-04 01:31:37